|1.||Smith, Steven R: 7 articles (10/2014 - 03/2009)|
|2.||Fletcher, Paul J: 6 articles (02/2016 - 04/2012)|
|3.||Higgins, Guy A: 6 articles (02/2016 - 04/2012)|
|4.||Shanahan, William R: 6 articles (10/2014 - 03/2009)|
|5.||Anderson, Christen M: 6 articles (07/2013 - 03/2009)|
|6.||Sanchez, Matilde: 5 articles (07/2013 - 07/2010)|
|7.||Weissman, Neil J: 4 articles (07/2013 - 07/2010)|
|8.||Aronne, Louis J: 3 articles (11/2015 - 03/2015)|
|9.||O'Neil, Patrick M: 3 articles (10/2014 - 07/2012)|
|10.||Bray, George A: 3 articles (08/2014 - 06/2013)|
|1.||Weight Loss (Weight Reduction)
10/01/2014 - "A significantly greater proportion of lorcaserin-treated patients achieved a weight loss of ≥ 10% (lorcaserin, 22.4%; placebo, 8.7%). "
07/01/2012 - "Lorcaserin was associated with significant weight loss and improvement in glycemic control in patients with type 2 diabetes."
10/01/2011 - "Lorcaserin administered in conjunction with a lifestyle modification program was associated with dose-dependent weight loss that was significantly greater than with placebo."
07/15/2010 - "In conjunction with behavioral modification, lorcaserin was associated with significant weight loss and improved maintenance of weight loss, as compared with placebo. "
03/01/2009 - "This study evaluated the safety and efficacy of lorcaserin for weight reduction in obese patients during a 12-week period. "
01/01/2010 - "Despite these promising results, additional experimental and clinical studies are critical for the approval of lorcaserin as a new anti-obesity monodrug therapy by the US Food and Drug Administration."
11/01/2013 - "The safety and efficacy of lorcaserin in the management of obesity."
02/01/2015 - "The present study is a back translational investigation into the effect of 28-day lorcaserin treatment in a diet-induced obesity (DIO) model using male, Sprague-Dawley rats. "
09/01/2014 - "Although existing trials have not demonstrated any significant issues with PHEN/TPM ER-induced heart rate elevation and lorcaserin-induced valvulopathy, all safety concerns should be seriously taken into account in patients treated with either of these novel anti-obesity medications. "
05/01/2014 - "None of the trials examined the impact of lorcaserin on the clinical complications of obesity. "
11/01/2011 - "Lorcaserin, a 5-HT(2C) agonist, has demonstrated efficacy in patients who are obese or are overweight with associated comorbidities. "
03/01/2011 - "In a double-blind, randomized, placebo-controlled trial, 57 (39 women) overweight and obese (body mass index, 27-45 kg/m(2)) adults were randomized to placebo (n = 28) or 10 mg twice daily lorcaserin (n = 29) for 56 d. "
07/15/2010 - "In this double-blind clinical trial, we randomly assigned 3182 obese or overweight adults (mean body-mass index [the weight in kilograms divided by the square of the height in meters] of 36.2) to receive lorcaserin at a dose of 10 mg, or placebo, twice daily for 52 weeks. "
11/01/2015 - "The results of the ongoing cardiovascular outcomes trial (CAMELLIA TIMI 61) will determine the role of lorcaserin in primary prevention of diabetes in overweight/obese individuals and its use in the high-risk population of patients with established cardiovascular disease or multiple cardiovascular risk factors."
04/01/2013 - "In three large randomized, double-blind, multicentre studies, oral lorcaserin was more effective than placebo in the management of obese and overweight adults with or without type 2 diabetes mellitus. "
|4.||Schizophrenia (Dementia Praecox)
|5.||Central Nervous System Diseases (CNS Diseases)
|3.||5-HT2C Serotonin Receptor
|9.||8- chloro- 2,3,4,5- tetrahydro- 1- methyl- 1H- 3- benzazepine
|10.||Serotonin (5 Hydroxytryptamine)
|1.||Drug Therapy (Chemotherapy)